In recent years, trials of sodium benzoate, a D-amino acid oxidase inhibitor, have been contacted for the treatment of mild AD [22], autism [23], schizophrenia [24], resulting in symptomatology improvement of patients. This evidence concerns the gene DAO and schizophrenia.